Pandemic Response Box library screening data. by Rodrigo Rollin-Pinheiro (239450)

Cytotoxicity assay. by Rodrigo Rollin-Pinheiro (239450)

Screening of the Pandemic Response Box^® library. by Rodrigo Rollin-Pinheiro (239450)

Gender-specific incidence trends of HFMD in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Effect of alexidine, amorolfine and olorofim on preformed biofilms of <i>Scedosporium</i> and <i>Lomentospora</i> species. by Rodrigo Rollin-Pinheiro (239450)

Effect of alexidine, amorolfine and olorofim on biofilm formation of <i>Scedosporium</i> and <i>Lomentospora</i> species. by Rodrigo Rollin-Pinheiro (239450)

Effects of soil microorganisms application to substrates of different organic matter content on Quantum Yield (QY) (A) and Normalized Difference Vegetation Index (NDVI) (B) in toma... by Robert Pokluda (8871407)

Immunofluorescence of select extracellular matrix (ECM) components. by Melissa A. MacIver (12850566)

“…<p>Matched sections from traditional histology (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0269571#pone.0269571.g008" target="_blank">Fig 8</a>) were assessed via immunofluorescence for aggrecan, Collagen Type II, and Collagen Type X. …”

SEM examination on corneal epithelial cells at different time points after exposure (A) At post-exposure 1 hour, no obvious superficial epithelial sloughing, or increased intercell... by Chun-Ting Lai (791855)

BQSR recalibration inaccuracies due to limited size and coverage of the ERCC spike-in standards, compared to the inaccuracies caused by recalibrating from the genome excluding know... by Justin M. Zook (146772)

Period of influence of each daily variable on the pod status change, from healthy to diseased with no signs of sporulation, 40 to 50 days after tagging. by Mariela E. Leandro-Muñoz (4487608)

Histogram of dorsum PROM divided into classifications and measured with an electrogoniometer. by Mark P. Wilhelm (9258177)

Exposure to a stressor activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system resulting in changes to the commensal flora (including a decrease in prevote... by Thomas Maslanik (295204)

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”